Nautilus Biotechnology Inc (NAUT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) has a cash flow conversion efficiency ratio of -0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.03 Million) by net assets ($169.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NAUT stock market capitalisation for the company's overall valuation and market capitalisation.
Nautilus Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Nautilus Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nautilus Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nautilus Biotechnology Inc ranked by their cash flow conversion efficiency. Explore Nautilus Biotechnology Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fino Payments Bank Limited
NSE:FINOPB
|
0.010x |
|
Shieh Yih Machinery Industry Co Ltd
TWO:4533
|
-0.052x |
|
Alicon Castalloy Limited
NSE:ALICON
|
0.185x |
|
Daehan Green Power Corporation
KQ:060900
|
-0.002x |
|
Reef Casino Trust
AU:RCT
|
0.925x |
|
Hanpin Electron Co Ltd
TW:2488
|
-0.019x |
|
Chongkundang
KO:001630
|
0.029x |
|
Epileds Technologies Inc
TW:4956
|
0.021x |
Annual Cash Flow Conversion Efficiency for Nautilus Biotechnology Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Nautilus Biotechnology Inc from 2018 to 2024. View latest Nautilus Biotechnology Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $208.73 Million | $-59.15 Million | -0.283x | -45.40% |
| 2023-12-31 | $265.35 Million | $-51.71 Million | -0.195x | -33.98% |
| 2022-12-31 | $314.92 Million | $-45.81 Million | -0.145x | -34.76% |
| 2021-12-31 | $363.58 Million | $-39.24 Million | -0.108x | -122.92% |
| 2020-12-31 | $-29.72 Million | $-14.00 Million | 0.471x | +187.98% |
| 2019-12-31 | $18.05 Million | $-9.66 Million | -0.535x | +98.88% |
| 2018-12-31 | $5.00 Million | $-238.30 Million | -47.660x | -- |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical… Read more